Autopsy report · NCT05121402

Safety and Efficacy Study of TLL018 in the Treatment of Ulcerative Colitis

“Decisions made by senior management of the company”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

TLL Pharmaceutical, LLC

Sponsor type

Industry

Conditions

Ulcerative Colitis

Interventions

TLL018; Placebo

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive
  “Senior managemnt decision” (83% match in meaning)
• Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%
  “Management Decision” (76% match in meaning)
• Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
  “Company decision” (72% match in meaning)
• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
  “Company's decision” (70% match in meaning)
• Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
  “Company business decision” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.